News - OBI Pharma

2026.Mar.12

Corporate

Award & Certification

OBI Is Awarded ABEA 2026 “Best ADC Developer in Taiwan”
CEO Heidi Wang Receives Women’s Leadership in ADC Development Award

2026.Mar.03

Corporate

OBI Receives Acceptance of Ten Abstracts at 2026 AACR
Advances Next-Generation ADC Development and Global Partnerships

2026.Feb.24

Corporate

OBI Presents Next-Generation Bispecific Dual-Payload ADC Development at World ADC London 2026

2025.Dec.19

Corporate

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

2025.Dec.18

Corporate

OBI Investors’ Meeting Highlights Value Transformation Driven by ADC Innovation

2025.Dec.09

Corporate

OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025

2025.Dec.05

Corporate

OBI-902 Receives Consecutive FDA Orphan Drug Designation
Indication Expanded to Gastric Cancer Including Gastroesophageal Junction Adenocarcinoma

2025.Nov.16

Corporate

OBI-902 has been granted by US FDA for Orphan Drug Designation for the treatment of Cholangiocarcinoma.

2025.Oct.21

Sustainability

OBI Volunteers Actively Participated in TBCA’s Pink October Event to Support Breast Cancer Awareness and Prevention

2025.Oct.08

Award & Certification

OBI Chairman Dr. Kung-Yee Liang Receives the 2024–2025 Presidential Science Prize

Announcements

Latest announcements

Events

Latest events